Ginkgo bioworks advances collaboration with novo nordisk on expression systems for pharmaceutical products

Boston , july 11, 2023 /prnewswire/ -- ginkgo bioworks (nyse: dna), which is building the leading platform for cell programming and biosecurity, today announced the completion of the pilot phase of their previously announced partnership with novo nordisk, a leading global healthcare company, to develop expression systems for pharmaceutical products. with the pilot phase completed and the first milestone achieved, the two companies will now move into the development phase to work towards making a more effective production process.
DNA Ratings Summary
DNA Quant Ranking